1. In Vivo
  2. >>Archive

Sybron Quietly Builds a Powerhouse

Sybron International, hardly a well-known name in the diagnostics industry, has built a $350 million highly profitable diagnostics business by acquiring small, niche companies. Its latest acquisition, Microgenics Corp., makes it an important player in the drugs of abuse and therapeutic drug monitoring businesses. Microgenics had been part of Boehringer Mannheim Corp. But when Roche bought Boehringer Mannheim, the FTC required Roche to sell off Microgenics for anti-trust reasons. Microgenics was sold last summer to an investor group, which sold it to Sybron.

Hardly a well-known name, Sybron International Corp. , has quietly amassed a $350 million highly profitable diagnostics business over the years by acquiring well-run niche companies—and now considers itself the tenth largest company in the industry. Its latest acquisition, Microgenics Corp. [See Deal], strengthens its position in one of its core businesses—making reagents for drugs of abuse (DOA) testing and therapeutic drug monitoring (TDM).

Sybron is already a major OEM supplier of TDM and DOA reagents to Roche , Beckman Coulter Inc. ...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Eleanor Malone

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Early Development Deals: Ipsen's Strategy For Biomarker-Driven Success

 
• By Eliza Slawther

Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.   

Shape Our Content: Take The Reader Survey

 
• By Eleanor Malone

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.

Sponsored by:

Prioritizing Safety in CAR-T Therapy: Patient Monitoring with Cerba Research’s Testing Portfolio

The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.

More from In Vivo

Podcast: Poolbeg CEO On The Biotech’s Big Bet On Small Molecules

 
• By Jo Shorthouse

In the latest episode of the In Vivo Podcast, Jeremy Skillington, CEO of Poolbeg Pharma, discussed the company’s ambitious pipeline and strategic direction.

video
Sponsored by:

Meeting the demands of the global biologics market

Lonza is addressing the growing global demand for biologics by utilizing its expert teams and the advanced capabilities of its newly acquired large-scale manufacturing site in Vacaville, California. Joanna McCafferty, Director of Commercial Development, shares more in this brief video. Ask ChatG

Mapping The Power And Potential Of Europe’s Market Access Collaborations

 
• By Leela Barham

Understand who’s influencing access decisions and how pharma can engage strategically across the continent.